Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ifx-1

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InflaRx Receives CHMP Opinion for GOHIBIC® in SARS-CoV-2 ARDS
    InflaRx Receives CHMP Opinion for GOHIBIC® in SARS-CoV-2 ARDS

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2981948/0/en/InflaRx-Receives-Positive-CHMP-Opinion-for-GOHIBIC-Vilobelimab-for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    InflaRx Reports Q3 2024 Financial Results & Business Update
    InflaRx Reports Q3 2024 Financial Results & Business Update

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977580/0/en/InflaRx-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    InflaRx Reports Q2 2024 Results And Provides Business Update
    InflaRx Reports Q2 2024 Results And Provides Business Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926834/0/en/InflaRx-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    InflaRx Announces Initiation of its Commitment Program for GOHIBIC
    InflaRx Announces Initiation of its Commitment Program for GOHIBIC

    25 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/25/2816626/0/en/InflaRx-Announces-Initiation-of-its-Commitment-Program-for-GOHIBIC-vilobelimab-to-Help-Broaden-Access-for-Eligible-Patients.html

    GLOBENEWSWIRE
    25 Jan 2024
    Share Share
    InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab
    InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab

    06 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/06/2773976/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-III-Trial-with-Vilobelimab-in-Pyoderma-Gangrenosum.html

    GLOBENEWSWIRE
    06 Nov 2023
    Share Share
    InflaRxs Marketing Authorization Application (MAA) for Vilobelimab
    InflaRxs Marketing Authorization Application (MAA) for Vilobelimab

    30 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/30/2734224/0/en/InflaRx-s-Marketing-Authorization-Application-MAA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency-EMA.html

    GLOBENEWSWIRE
    30 Aug 2023
    Share Share